Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio (2009 - 2026)
Bristol Myers Squibb's (CELG-RI) quarterly Dividend Coverage Ratio came in at 2.58 in Q2 2026, up 147.65% year-over-year from 1.04 in Q2 2025, and up 23.39% quarter-over-quarter from 2.09 in Q1 2026.
Analysis
Bristol Myers Squibb (CELG-RI) Dividend Coverage Ratio (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Dividend Coverage Ratio for 18 consecutive years, with 2.58 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Dividend Coverage Ratio rose 147.65% year-over-year to 2.58 in Q2 2026; TTM through Jun 2026 was 1.82, a 78.04% increase from a year earlier, with the FY2025 full-year figure at 1.4, up 176.14% from the prior year.
- Dividend Coverage Ratio was 2.58 for Q2 2026 at Bristol Myers Squibb, up from 2.09 in the prior quarter.
- Over five years, Dividend Coverage Ratio peaked at 119.08 in Q2 2022 and troughed at 9.83 in Q1 2024.
- A 5-year average of 7.39 and a median of 1.57 in 2023 frame the typical range for Dividend Coverage Ratio.
- Across the five-year window, Dividend Coverage Ratio sank 618.34% in 2024 and soared 1279.13% in 2025, its largest moves.
- Over 5 years, Dividend Coverage Ratio stood at 1.77 in 2022, then dropped by 14.11% to 1.52 in 2023, then slumped by 95.89% to 0.06 in 2024, then soared by 1279.13% to 0.86 in 2025, then jumped by 199.41% to 2.58 in 2026.
- The last three Dividend Coverage Ratio figures came in at 2.58 (Q2 2026), 2.09 (Q1 2026), and 0.86 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1.71 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1.18 |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -0.62 |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 1.14 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -0.10 |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 0.07 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | - |
| 10 | Bristol Myers Squibb | 285.98 Mn | -10.78 Bn | 9.25 Bn | 2.58 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 |
| Mar 31, 2026 | 2.09 |
| Dec 31, 2025 | 0.86 |
| Sep 30, 2025 | 1.74 |
| Jun 30, 2025 | 1.04 |
| Mar 31, 2025 | 1.96 |
| Dec 31, 2024 | 0.06 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | 1.38 |
| Mar 31, 2024 | -9.83 |
| Dec 31, 2023 | 1.52 |
| Sep 30, 2023 | 1.62 |
| Jun 30, 2023 | 1.74 |
| Mar 31, 2023 | 1.90 |
| Dec 31, 2022 | 1.77 |
| Sep 30, 2022 | 1.39 |
| Jun 30, 2022 | 119.08 |
| Mar 31, 2022 | 1.08 |
| Dec 31, 2021 | 2.16 |
| Sep 30, 2021 | 1.42 |